Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Calls For More Studies Of Mini-Slings For Urinary Incontinence

This article was originally published in The Gray Sheet

Executive Summary

FDA’s Obstetrics and Gynecology Device panel recommends second-generation mini-slings to treat stress urinary incontinence be subject to 510(k) pre-market clinical trial requirements and additional post-market data collection mandates.

You may also be interested in...

Surgical Mesh And Sling Devices Must Undergo Post-Market Studies

FDA sends post-market study orders to 33 manufacturers of urogynecologic surgical mesh used for pelvic organ prolapse and to seven makers of single-incision mini-slings used for stress urinary incontinence.

FDA Panel: Transvaginal Mesh For Prolapse Should Be Class III

Current and future surgical mesh devices for pelvic organ prolapse repair would require PMA submissions under a recommendation last week by FDA’s Obstetrics and Gynecology Devices panel.

Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue

At advisory committee meeting on Acrotech's two peripheral T-cell lymphoma drugs, FDA reviewers suggest they are more willing to seek product withdrawal for failure to conduct studies with due diligence when there are numerous available therapies.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts